Aerie Pharmaceuticals
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various eye diseases, including glaucoma, dry eye, and retinal conditions. The company’s notable products include Rhopressa, a once-daily eye drop designed to lower elevated intraocular pressure in patients with glaucoma or ocular hypertension, and Rocklatan, a fixed-dose combination of Rhopressa and latanoprost for treating open-angle glaucoma and ocular hypertension. Additionally, Aerie is developing several clinical-stage candidates, including AVX-012 for dry eye and AR-1105 and AR-13503, which are sustained-release implants aimed at retinal diseases. The company was founded in 2005 and is headquartered in Durham, North Carolina, with research facilities located in Research Triangle Park. Aerie Pharmaceuticals has also established collaborative agreements for research and development initiatives.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.